Tag: REGN10933

Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2

pharmanewsdaily- June 12, 2020

US biotech company Regeneron Pharmaceuticals has started the first clinical trial of its investigational dual antibody cocktail REGN-COV2 (REGN10933+REGN10987) for the prevention and treatment of ... Read More